sciencePipeline Spotlight

Retatrutide Preview

Eli Lilly's triple-agonist candidate hits three receptors instead of two. Phase 2 data set a new ceiling for trial weight loss. Phase 3 is underway.

Tirzepatide opened the door to multi-receptor agonists in metabolic medicine. Retatrutide is the next door — a single molecule that activates three receptors: GIP, GLP-1, and glucagon. It is Eli Lilly's most ambitious metabolic candidate to date, and the Phase 2 data published in 2023 set a new headline number for trial weight loss with a GLP-1-class drug.

Retatrutide is not yet FDA-approved. The Phase 3 program (TRIUMPH) is still running. Dosing, labeling, indications, side-effect profile, and headline efficacy numbers may all change before the drug reaches pharmacies. Treat everything here as a snapshot of where the science stood at the time of writing.

For patients tracking what's next in this category, retatrutide is the candidate to know. Here's what is in the published record so far.

What it is

Retatrutide is a once-weekly subcutaneous injection. Each molecule binds three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. The first two overlap with tirzepatide. The third — glucagon agonism — is what differentiates retatrutide from every other approved GLP-1-class drug.

Glucagon activation, in isolation, raises blood glucose. Paired with GIP and GLP-1 activity in a single molecule, it appears to drive additional energy expenditure and possibly liver fat reduction, while the GLP-1 and GIP components prevent the glucose-raising effect from dominating. The mechanism is genuinely novel for the obesity space.

The Phase 2 trial published in NEJM in 2023 ran retatrutide at doses up to 12 mg weekly in adults with obesity. The headline result: mean body weight reduction of approximately 24 percent at 48 weeks at the highest dose, with the trial still showing weight loss continuing at endpoint. For context, tirzepatide's SURMOUNT-1 reported approximately 20.9 percent at 72 weeks at the 15 mg dose.

How it compares

Versus tirzepatide (Zepbound), retatrutide produced a higher mean weight loss in Phase 2 over a shorter trial period. That comparison is informal — different trials, different populations, different endpoints — but it has driven the hype around the triple agonist. Phase 3 will produce the direct apples-to-apples picture.

Versus semaglutide (Wegovy), retatrutide's Phase 2 numbers are well above STEP 1's mean of approximately 14.9 percent. Again, cross-trial comparison comes with caveats, but the direction is clear.

The side-effect profile in Phase 2 looked similar to other GLP-1-class drugs: predominantly gastrointestinal, dose-dependent, more pronounced during titration. Cardiovascular safety and longer-term metabolic effects are exactly what Phase 3 is designed to characterize. The unique glucagon component requires careful follow-up.

FDA approval timing is uncertain. Most analysts expect Eli Lilly to file for retatrutide approval between 2026 and 2027 if Phase 3 reads out positively. The first indication is likely to be chronic weight management, with type 2 diabetes and possibly MASH (metabolic dysfunction-associated steatohepatitis) following.

What to know if you're considering it

Watching retatrutide from the sidelines

hourglass_top

Not yet prescribable

Retatrutide is in Phase 3. It is not FDA-approved, not commercially available, and not legally compoundable. Anyone claiming to sell it outside a clinical trial is operating outside the legitimate supply chain.

experiment

Phase 3 changes things

Phase 2 data is encouraging, not final. Dose ranges, side-effect profile, and headline efficacy can all shift when larger and longer trials report.

schedule

Earliest realistic timeline

If TRIUMPH reads out cleanly, approval most likely lands in 2026 to 2027. Insurance access and pricing will lag launch by months.

Common questions

Common Concerns

When will retatrutide be available?expand_more

The earliest realistic FDA approval window is 2026 to 2027, contingent on Phase 3 data. After approval, manufacturer launch, insurance coverage, and pharmacy supply each add lead time. Treat any specific date as speculation until Lilly files.

Is retatrutide better than Zepbound?expand_more

In Phase 2 versus historical SURMOUNT-1 results, retatrutide produced larger mean weight loss. That is not a direct head-to-head trial. Phase 3 will be more comparable, but a true comparative study would be the cleanest answer.

Can I get retatrutide from a compounding pharmacy?expand_more

No. Retatrutide is not FDA-approved and cannot be legally compounded. Anything sold under that name outside an authorized clinical trial is unverified and unsafe.

Will the glucagon component cause blood sugar problems?expand_more

Trial data so far suggests the combined GIP/GLP-1/glucagon mechanism does not raise blood glucose in practice — the GLP-1 and GIP arms appear to dominate. Phase 3 will give a fuller picture, especially in patients with diabetes.

Keep exploring

Browse all GLP-1 guides.